Jobevne is a recombinant humanised monoclonal antibody which functions as a vascular endothelial growth factor inhibitor ...

Biocon Biologics has received the Food and Drug Administration’s green light for Jobevne (bevacizumab-nwgd), a biosimilar ...

Biocon's stock price increased almost 4 per cent in the early trading session on 11 April after the company’s subsidiary ...

In 2023, bevacizumab sales in the U.S. were around $2.0 billion. Biocon Biologics serves over 5 million patients each year ...

Bengaluru: Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, has announced that the U.S. Food and Drug Administration ...

B12019 and Neulasta are formulations of pegfilgrastim, a pegylated form of the granulocyte colony-stimulating factor analog filgrastim, which mitigates the negative effects of chemotherapy on the ...

The FDA has approved Sandoz’s pegfilgrastim biosimilar ... market since last year and is a granulocyte colony stimulating factor (GCSF) class drug. Approval of Ziextenzo was based on a dossier ...

Biocon Biologics Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved JOBEVNE™ (bevacizumab-nwgd), a ...